Ricevi le ultime notizie sulle azioni Biomea Fusion con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di BMEA

Ultime notizie per

BIOMEA FUSION INC

Biomea Fusion

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Biomea Fusion Inc

News

Financing

Press Releases

Biomea Fusion Announces Pricing of Public Offering of Securities

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates

General

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Management

Biomea Fusion Appoints Julianne Averill to its Board of Directors

Earnings

Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights

Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Health Care

Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations

Biomea Fusion Announces Proposed Public Offering of Securities

BMEA

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

aTyr Pharma

Coya Therapeutics

Entera Bio

EXoZymes

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

TuHURA Biosciences

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Immix Biopharma

Opus Genetics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

MDxHealth

Macrogenics

Metagenomi

Oncolytics Biotech

Ovid Therapeutics

Quince Therapeutics

AVITA Medical

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Surrozen

Shattuck Labs

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

D. Boral Capital

Jefferies

Citigroup

Scotiabank

Piper Sandler

Comments

Biomea Fusion Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO